GRZEGORZ KAMINSKI

Head of the Department/Professor

Military Institute of Medicine National Research Institute

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Grzegorz Kaminski is a Professor and Head of the Department at the Military Institute of Medicine - National Research Institute in Poland. His research areas include neuroendocrine neoplasms, endocrine disorders, and the complications of radioligand therapy. Recent publications reflect his expertise in diagnostic methodologies and clinical case presentations related to various endocrine conditions.

Articles (29)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

Wojskowy Instytut Medyczny

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

GRZEGORZ KAMINSKI

Research Interests

Explore related searches

Contact this professor

About

Articles (29)

Thymic well-differentiated neuroendocrine tumor with isolated bone marrow metastases: an unusual metastatic pattern

Comparison of Localization Methods in Cushing Disease—Could [11C]C-Methionine PET/CT Replace MRI or BIPSS?

Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate.

Idiopathic hypogonadotropic hypogonadism as a cause of delayed puberty

Massive recurrent cysts of ovaries with oligomenorrhea as a clinical manifestation of pituitary gonadotropinoma

The Use of [11C]C-Methionine in Diagnostics of Endocrine Disorders with Focus on Pituitary and Parathyroid Glands

Angiogenic biomarkers of response to treatment with peptide receptor radionuclide therapy in neuroendocrine tumours.

Diagnostic and treatment difficulties of carcinoid heart disease. Clinical case presentation

Thyroid Cancer in Regions Most Contaminated after the Chernobyl Disaster.

A nuclear beacon of hope: an advanced, metastatic glucagonoma treated with [177Lu]Lu-DOTA-TATE.

Recent guidelines for diagnostic and therapeutic management of accidentally detected adrenal tumours (incidentaloma) in adults.

The challenging differential diagnosis of recurrent flushing episodes: systemic mastocytosis mimicking carcinoid syndrome.

Theranostics in Renal Cell Carcinoma—A Step Towards New Opportunities or a Dead End—A Systematic Review

Adverse Events of Radioligand Therapy in Patients with Progressive Neuroendocrine Neoplasms: The Biggest Eastern European Prospective Study

TSH Stimulation before PET/CT as Our Frenemy in Detecting Thyroid Cancer Metastases—Final Results of a Retrospective Analysis

23th Day of Andrology – Report from the Conference of Polish Society of Andrology 2022

Male hypogonadism - practical guidlines

Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors-Extended Analysis of Potential Acute and Chronic Complications.

Utility of non-contrast Dual Energy Computed Tomography in diagnosis of differentiated thyroid cancer - two case study.

Basics of prevention and management of iodine-based contrast media-induced thyroid dysfunction - position paper by the Polish Society of Endocrinology.

Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center

Remarkable regression of inoperable pancreatic grade 3 neuroendocrine neoplasm after radioligand therapy with [177Lu]Lu-DOTATATE and [90Y]Y‑DOTATATE.

A case of patient with suspicious, rapidly growing thyroid tumor, with a short review of the thyroid nodular disease guidelines

Radioligand Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE or [<sup>177</sup>Lu]Lu-DOTA-TATE and [<sup>90</sup>Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade.

Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms.

Usefulness of PET/CT with Carbon-11-Labeled Methionine in the Diagnosis of Tertiary Hyperparathyroidism.

Changes of lipid profile in subclinical hyperthyroidism and following restoration of euthyroidism.

Delay in Diagnosis of Autoimmune Polyendocrine Syndrome Type 2 as a Consequence of Misinterpretation of Gastrointestinal Symptoms.

Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms-A Preliminary Study.

Collaborators (6)

Beata Kos-Kudła

Marek Bolanowski

Jakub Kucharz

Monika Wójcik-Giertuga

ARKADIUSZ ZEGADŁO

Katarzyna Agnieszka Gniadek-Olejniczak

Make your next move.